Jan H M Schellens

发表

Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.

Dejan Juric, Jordi Rodon, Alan Huang, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time.

Henk-Jan Guchelaar, Jesse J Swen, J. Schellens, 2016, European journal of cancer.

Identification of serum proteins discriminating colorectal cancer patients and healthy controls using surface-enhanced laser desorption ionisation-time of flight mass spectrometry.

Jos H Beijnen, J. Schellens, J. Beijnen, 2006, World journal of gastroenterology.

An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons.

Jos H Beijnen, Irma Meijerman, J. Schellens, 2003, Toxicology and applied pharmacology.

Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecin.

S. Bates, J. Schellens, D. Ross, 2003, Cancer research.

Clinical experience with aurora kinase inhibitors: a review.

Jos H Beijnen, David S Boss, J. Schellens, 2009, The oncologist.

Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer.

Gary Middleton, Takayuki Yoshino, Chloe E Atreya, 2018, Cancer discovery.

Development and validation of an enzyme-linked immunosorbent assay for the quantification of trastuzumab in human serum and plasma.

Jos H Beijnen, David S Boss, C. Damen, 2009, Analytical biochemistry.

Quantitative bioanalysis of peptides by liquid chromatography coupled to (tandem) mass spectrometry.

Jos H Beijnen, Irene van den Broek, J. Schellens, 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.

Jan Lubinski, Alan Ashworth, Susan Shanley, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Concise drug review: azacitidine and decitabine.

Jos H Beijnen, J. Schellens, J. Beijnen, 2013, The oncologist.

The biological and clinical role of drug transporters at the intestinal barrier.

Jos H Beijnen, J. Schellens, J. Beijnen, 2009, Cancer treatment reviews.

Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.

Manuel Hidalgo, Martin Schuler, Fabrice Andre, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Improved pharmacodynamic (PD) assessment of low dose PARP inhibitor PD activity for radiotherapy and chemotherapy combination trials.

Conchita Vens, Heike Peulen, J. Schellens, 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Bioanalytical methods for the quantification of therapeutic monoclonal antibodies and their application in clinical pharmacokinetic studies.

Jos H Beijnen, C. Damen, J. Schellens, 2009, Human antibodies.

Clinical proteomics: searching for better tumour markers with SELDI-TOF mass spectrometry.

Marie-Christine W. Gast, Jos H Beijnen, Marie-Christine W Gast, 2006, Trends in pharmacological sciences.

The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine.

Jos H Beijnen, J. Schellens, J. Beijnen, 2003, Cancer research.

Photodynamic therapy in oncology.

Paul Baas, F. Stewart, J. Schellens, 2006, The oncologist.

Lapatinib for advanced or metastatic breast cancer.

Henk-Jan Guchelaar, Jos H Beijnen, J. Schellens, 2012, The oncologist.